ASCO 2020 - Wrap Up
Clinical Activity of the RET Inhibitor Pralsetinib (BLU-667) in Patients with RET-Altered Solid Tumors
AcceleRET Lung: A Phase 3 Study of Pralsetinib in Patients with RET Fusion–Positive Metastatic NSCLC
An updated analysis of 3 phase 1/2 trials finds that entrectinib continues to demonstrate clinically meaningful responses in patients with NTRK fusion–positive solid tumors, including those with and without baseline central nervous system disease.
Next-Generation RET Inhibitor TPX-0046 Is Active in Drug-Resistant and Naïve RET-Driven Cancer Models
Efficacy of Amivantamab (JNJ-61186372) in Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation
Barriers to Targeted Therapies for NSCLC Patients with Highly Actionable Gene Variants in the Veterans Health Affairs Program
Results 1 - 10 of 10